Preview

Атеротромбоз

Расширенный поиск

СЛОЖНОСТИ ВЫБОРА АНТИКОАГУЛЯНТНОЙ ТЕРАПИИ У БОЛЬНЫХ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ И КОРОНАРНЫМ АТЕРОСКЛЕРОЗОМ: МЕСТО НОВЫХ АНТИКОАГУЛЯНТОВ К 2014 г.

https://doi.org/10.21518/2307-1109-2014-1-35-42

Полный текст:

Аннотация

.

Об авторе

О. В. Аверков
Городская клиническая больница №15 имени О.М. Филатова и Российский университет дружбы народов, Москва
Россия


Список литературы

1. Hurlen M, Abdelnoor M, Smith P, et al.: Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002, 347: 969-974.

2. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2012 Jul, 33 (13): 1635-701.

3. Camm AJ, Kirchhof P, Lip G YH, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), European Heart Journal, 31, 19, 2369-2429, 2010.

4. Paikin JS, Wright DS, Crowther MA, Mehta SR, Eikelboom JW.Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation. 2010, 121: 2067-2070.

5. Dewilde W Jm, Oirbans T, Verheugt FWA, for the WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013, DOI: 10.1016/S0140–6736 (12) 62177-1.

6. Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy in stable coronary artery disease in atrial fibrillation patients on oral anticoagulant: a nationwide cohort study. Circulation 2014, DOI: 10.1161/circulationaha.113.004834.

7. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: metaanalysisof noninferiority randomized controlled trials. A Arch Intern Med. 2012 Mar 12, 172 (5): 397-402.

8. Ezekowitz MD, Reilly PA, Nehmiz G et al. Dabigatranwith orwithout concomitant Aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO). Am J Cardiol. 2007 Nov 1, 100 (9): 1419-26.

9. Furugori T, Sugiyama N, Morishima Y. Shibano T. Anthithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombmodulin-protein C system. Thromb Haemost, 2011, 106: 1076-1083.

10. Mak K-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomized trials. BMJ 2012, 2e001592.

11. Heidbuchel H, Verhemme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulations in patients with non-valvular atrial fibrillation. Europace (2013), 15, 625-651.


Для цитирования:


Аверков О.В. СЛОЖНОСТИ ВЫБОРА АНТИКОАГУЛЯНТНОЙ ТЕРАПИИ У БОЛЬНЫХ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ И КОРОНАРНЫМ АТЕРОСКЛЕРОЗОМ: МЕСТО НОВЫХ АНТИКОАГУЛЯНТОВ К 2014 г. Атеротромбоз. 2014;(1):44-49. https://doi.org/10.21518/2307-1109-2014-1-35-42

For citation:


Аверков О.В. Atherothrombosis Journal. 2014;(1):44-49. (In Russ.) https://doi.org/10.21518/2307-1109-2014-1-35-42

Просмотров: 255


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)